Nice, looks like they have a similar outcome in the second cohort as the first. What sounds like disease control in 2 out of 3 patients. Maybe we will see these progress to a partial response or complete response down the track, as it can take time. But for now safety is still in tack which is crucial.
But sounds like the third cohort is going to be the big one.. a big uptick in dosage and the best chance so far for some very strong data.
patience is key and it’s nice they are willing to share updates along the way to keep the investors informed … so far so good is what I’m reading!
goodluck all
Nice, looks like they have a similar outcome in the second...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
0.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $8.060M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.4¢ | $7.704K | 1.925M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 2980697 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 13492653 | 21 |
View Market Depth
| Last trade - 11.51am 24/06/2025 (20 minute delay) ? |
| CHM (ASX) Chart |